Amarin Corporation plc · NASDAQ:AMRN

Amarin — Investor Presentation (November 2005)

23 slides from Amarin's investor presentation, November 2005

  1. Slide 1: The Future in Mind

    CORPORATION PLC THE FUTURE IN MIND

  2. Slide 2: Safe Harbour

    SAFE HARBOUR DISCLOSURE NOTICE: The information contained in this document is as of November, 2005. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking

  3. Slide 3: Neuroscience company focused on novel drugs for CNS disorders

    Neuroscience company focused on research, development and commercialization of novel drugs for CNS disorders COMMERCIAL HIGHLIGHTS KEY FACTS Late stage development pipeline • UK based, US focused • Risk managed portfolio • 26 employees Lead product – Miraxion • NASDAQ (ticker: AMRN) • PIII for Hunti

  4. Slide 4: Management Team

    MANAGEMENT TEAM Rick Stewart Chief Executive Officer Alan Cooke Chief Financial Officer Dr Mehar Manku Head of Research & Development Dr Tony Clarke VP Clinical Development Darren Cunningham EVP Strategic Development David Boal Business Development Director 4

  5. Slide 5: Neurology Focus

    NEUROLOGY FOCUS U.S. CNS MARKET $41bn Significant unmet medical need Market - double digit annual growth Neurology Aging U.S. demographics $12 bn Physicians covered by a modest size sales force Leverage management knowledge and U.S. NEUROLOGISTS 7,200 experience Previously established U.S. High neur

  6. Slide 6: Strategy

    STRATEGY Develop and directly market neurology products for U.S. Partner neuroscience pipeline for indications outside neurology and markets outside U.S. In-license additional novel neurology compounds for U.S. Goal: Leading neurology company 6

  7. Slide 7: Product Pipeline: Amarin Commercialisation

    PRODUCT PIPELINE: AMARIN COMMERCIALISATION DEVELOPMENT P/C I II III Miraxion Huntington's disease (US) Miraxion Undisclosed indication Comb. Lipid Neurodegeneration Amarin has an active in-licensing program for development stage neurology products for the U.S. market. Current development status 7

  8. Slide 8: Product Pipeline: Out-licensing/Partnering

    PRODUCT PIPELINE: OUT-LICENSING/PARTNERING DEVELOPMENT P/C I II III Miraxion Huntington's disease (EU*) Miraxion Depressive disorders LAX-201 Major Depression in women LAX-202 Multiple Sclerosis Fatigue (EU) IP CNS indications *Miraxion for HD in EU: • Already partnered for major EU market with Scil

  9. Slide 9: Miraxion

    MIRAXIONTM Miraxion is a semi-synthetic, highly purified derivative of (all- cis)-5,8,11,14,17- eicosapentaenoic acid (ethyl-EPA) Ethyl-EPA based prescription compounds are already approved by the regulatory authorities in Japan and the U.S. for cardiovascular indications Mechanism of action: • Regu

  10. Slide 10: Huntington's Disease ('HD')

    HUNTINGTON’S DISEASE (‘HD’) Devastating neurodegenerative disease No effective treatment currently available to patients Caused by high level of CAG repeats in specific genes Typically CAG repeats >36 denotes presence of HD Symptoms after age 30 with death in 10 to 25 years Severe movement disorders

  11. Slide 11: Miraxion for HD: Initial Phase III

    MIRAXION FOR HD: INITIAL PHASE III Large multi-centre 135-patient 12-month double-blind placebo-controlled trial Primary endpoint: Miraxion versus placebo on total motor score – 4 (‘TMS-4’) sub-scale of UHDRS Effect on primary endpoint, TMS-4: Group Patients Significance Intent to Treat (ITT) 135 No

  12. Slide 12: Miraxion for HD: CAG < 44 Group

    MIRAXION FOR HD: CAG < 44 GROUP Significant in ITT and PP groups at 6 months and 12 months Positive CAG data consistent across centres Group represents 65-70% of all HD patients Time course of TMS-4, ITT (LOCF), CAG ≤ 44 40 Placebo 35 Miraxion 30 25 6 month, p = 0.025 20 12 month, p = 0.029 15 12 ba

  13. Slide 13: Miraxion for HD: CAG < 44 Group

    MIRAXION FOR HD: CAG < 44 GROUP GROUP BASELINE CHANGE TO 12 M 25.4 + 11.8 0.0 + 6.8 (0%) ITT Placebo n=32 ITT Miraxion n=35 23.1 + 9.4 -3.5 + 7.5 (-15.2%) P-value of difference NS 0.029 PP Placebo n=22 24.5 + 12.6 +1.4 + 7.5 (+5.7%) PP Miraxion n=22 22.5 + 10.8 -5.1 + 7.9 (-22.7%) P-value of differe

  14. Slide 14: Miraxion for HD: Phase III Strategy

    MIRAXION FOR HD : PHASE III STRATEGY • Special Protocol Assessment (“SPA”) in place Consideration Initial Trial New Trials Patient entry criteria • All comers • CAG < 44 and less severe Protocol compliance • Too few centres (6) • 70 centres • Too few evaluations • More evaluations • 6 month extensio

  15. Slide 15: Depression

    Depressive Disorders in the U.S. DEPRESSION (approx 19 m) Annual U.S. sales of Bipolar Disorder antidepressants c$13 billion 12% Major Depression 65% to 75% not effectively treated 52% Miraxion offers a different and complementary mechanism of Other action to SSRI’s 36% Modification of neuronal memb

  16. Slide 16: Miraxion for Depression: Investigator-led Phase IIa studies

    MIRAXION FOR DEPRESSION Three Investigator led Phase IIa studies with Miraxion achieved statistical significance: Investigators Trial Details Indication Results N=20 Treatment 2g/d or placebo unresponsive Belmaker(I) p<0.05 for 4 wks depression N=75 Depression 1 or 2g/d or placebo for In bipolar Fra

  17. Slide 17: Miraxion for Depression: Melancholic Features

    MIRAXION FOR DEPRESSION: MELANCHOLIC FEATURES Peet & Horrobin Phase IIa study also achieved statistical significance in primary endpoint Post-hoc data analysis completed on three Amarin led phase IIa studies Identified that Miraxion showed a significant clinical benefit in patients with melancholic

  18. Slide 18: Miraxion for Depression: Summary

    MIRAXION FOR DEPRESSION: SUMMARY Phase IIa studies show promising results (adjunctive and monotherapy) Offers different and complementary mechanism of action to SSRI’s Identification of subgroup with melancholic features allows more accurate targeting of potentially responsive patients Patents grant

  19. Slide 19: Intellectual Property for Miraxion

    INTELLECTUAL PROPERTY FOR MIRAXION Miraxion in HD Miraxion in Depression • Orphan drug designation • Patent 40266 (granted) 7 years market exclusivity in US, Depression, Schizophrenia, valid up to 10 years in Europe until 2017, US and EU • Patent 40390 (pending) • Patent 40390 (pending) Use of Mirax

  20. Slide 20: Financial Summary

    FINANCIAL SUMMARY Q3-05 Q2-05 Q1-05 $ $ $ Operating Loss 4.6m 5.7m 3.3m • Increase driven by R&D investment Capitalisation Sep 30 • Cash position $13.7m • No debt • Common Shares1 51.4m • Options (avg exercise price $3.90) 4.5m • Warrants (avg exercise price $2.51) 0.8m 1Investors in May financing h

  21. Slide 21: Near Term Potential Milestones

    NEAR TERM POTENTIAL MILESTONES Amarin Commercialisation Out-licensing/Partnering Miraxion for HD Miraxion for Depression 2006 • First patient in Q3 05 • Last patient in Q2 06 Miraxion for HD • Last patient out Q4 06 (remaining EU markets) 2005/6 • Data available Late 06/Early 07 LAX-201 for depressi

  22. Slide 22: Investment Rationale

    INVESTMENT RATIONALE Valuable near term product pipeline Lead product, Miraxion in Phase III development: Under SPA and with Fast track designation Leveraged extensive data of initial Phase III HSG/Euro HD Established safety profile Multiple programs in Phase II and earlier Active in-licensing and o

  23. Slide 23: The Future in Mind

    CORPORATION PLC THE FUTURE IN MIND

Amarin — Investor Presentation (November 2005) on 6ix